Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,976 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Kantarjian H, et al. Among authors: shan j. Cancer. 2004 Dec 15;101(12):2788-801. doi: 10.1002/cncr.20668. Cancer. 2004. PMID: 15481055 Free article. Clinical Trial.
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Kantarjian HM, et al. Among authors: shan j. Clin Cancer Res. 2002 Jul;8(7):2167-76. Clin Cancer Res. 2002. PMID: 12114417 Clinical Trial.
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. Kantarjian HM, et al. Among authors: shan j. Cancer. 2003 Feb 15;97(4):1033-41. doi: 10.1002/cncr.11223. Cancer. 2003. PMID: 12569603 Free article.
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. O'Brien S, et al. Among authors: shan j. Cancer. 2003 Sep 1;98(5):888-93. doi: 10.1002/cncr.11620. Cancer. 2003. PMID: 12942553 Free article. Clinical Trial.
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. Kantarjian H, et al. Among authors: shan j. Cancer. 2003 Oct 1;98(7):1430-7. doi: 10.1002/cncr.11665. Cancer. 2003. PMID: 14508830 Free article.
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Kantarjian HM, et al. Among authors: shan j. Cancer. 2003 Dec 15;98(12):2636-42. doi: 10.1002/cncr.11831. Cancer. 2003. PMID: 14669283 Free article.
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Kantarjian H, et al. Among authors: shan j. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):68-75. doi: 10.1158/1078-0432.ccr-1035-3. Clin Cancer Res. 2004. PMID: 14734453
1,976 results